Fig. 1 · Structure

Documents & Downloads

Vincristine sulfate

Cat. No. A10973 CAS 2068-78-2

Tubulin inhibitor

Vincristine is a mitotic inhibitor, and is used in cancer chemotherapy.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
Microtubules (Cell-free assay) 32 μM

Cellular Effect

Cell Line Activity Value Description Reference
A549 IC50 171.5 nM Antiproliferative activity against human A549 cells after 48 hrs by MTT assay [PMID: 28038323]
A549 IC50 20 nM Cytotoxicity against human A549 cells after 72 hrs by alamar blue assay [PMID: 23215348]
BT-549 IC50 54.72 nM Antiproliferative activity against human BT549 cells after 48 hrs by MTT assay [PMID: 28038323]
Cancer cell lines GI50 0.1 μM Cytotoxicity against human colon cancer cells after 48 hrs [PMID: 24747749]
Cancer cell lines GI50 0.1 μM Growth inhibition of human colon cancer cells after 48 hrs [PMID: 20684599]
Cancer cell lines GI50 0.1 μM Growth inhibition of human colon cancer cell by NCI-CLS assay [PMID: 20395150]
Cancer cell lines GI50 0.1 μM Growth inhibition of human CNS cancer cell by NCI-CLS assay [PMID: 20395150]
Cancer cell lines GI50 0.1 μM Growth inhibition of human prostate cancer cell by NCI-CLS assay [PMID: 20395150]
Cancer cell lines GI50 0.13 μM Cytotoxicity against human prostate cancer cells after 48 hrs [PMID: 24747749]
Cancer cell lines GI50 0.13 μM Cytotoxicity against human CNS cancer cells after 48 hrs [PMID: 24747749]
Cancer cell lines GI50 0.13 μM Cytotoxicity against human CNS cancer cells after 48 hrs [PMID: 22283430]
Cancer cell lines GI50 0.13 μM Cytotoxicity against human prostate cancer cells after 48 hrs [PMID: 22283430]
Cancer cell lines GI50 0.13 μM Growth inhibition of human CNS cancer cells after 48 hrs [PMID: 20684599]
Cancer cell lines GI50 0.13 μM Growth inhibition of human prostate cancer cells after 48 hrs [PMID: 20684599]
Cancer cell lines GI50 0.3 μM Growth inhibition of human ovarian cancer cell by NCI-CLS assay [PMID: 20395150]
Cancer cell lines GI50 0.3 μM Growth inhibition of human renal cancer cell by NCI-CLS assay [PMID: 20395150]
Cancer cell lines GI50 0.3 μM Growth inhibition of human breast cancer cell by NCI-CLS assay [PMID: 20395150]
Cancer cell lines GI50 0.32 μM Cytotoxicity against human ovarian cancer cells after 48 hrs [PMID: 24747749]
Cancer cell lines GI50 0.32 μM Cytotoxicity against human renal cancer cells after 48 hrs [PMID: 24747749]
Cancer cell lines GI50 0.32 μM Cytotoxicity against human breast cancer cells after 48 hrs [PMID: 24747749]
Cancer cell lines GI50 0.32 μM Cytotoxicity against human ovarian cancer cells after 48 hrs [PMID: 22283430]

21 records · Scroll to view more

Vincristine sulfate Research Summary

This section summarizes 3 in vitro studies and 1 in vivo study of Vincristine sulfate from 3 published references. In vitro models include human leukemic MOLT-4 cells; bone marrow of wild-type animals.

Vincristine sulfate In Vitro Studies

Vincristine exhibited cytotoxicity against human leukemic MOLT-4 cells, with an IC50 of 3.3 nM at 48 h measured by MTT assay. Continuous incubation of bone marrow from wild-type animals with Vincristine at 100 ng ml−1 reduced colony numbers by more than 90% relative to control wells without the drug. In MOLT-4 cells, Vincristine alone at 3 nM was insufficient to affect mitochondrial membrane potential at 12, 24, 36, and 48 h. [1,2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Vincristine cytotoxicity in human leukemic cells

Cell-based study · human leukemic MOLT-4 cells [1]

Human leukemic MOLT-4 cells were treated with various concentrations of vincristine for 48 h, and viability was measured by MTT assay. Vincristine exhibited cytotoxicity with an IC50 of 3.3 nM.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Cell viability was measured by MTT assayIC50 IC50 of 3.3 nM[1]

Literature-Reported Treatment Conditions

Treatment concentration
various concentrations
Exposure duration
48 h
Vehicle
DMSO (dimethylsulfoxide)
Reported limits
Not stated in the sentences used: route, control.
Methods and source locations

Compound reported in the paper: Vincristine

The paper names Vincristine without stating the salt or form; not verified as the sulfate form supplied as A10973. No dose conversion or lot validation.

Results > Cytotoxic effects of vincristine and SAHA, alone and in combination, on human leukemic MOLT-4 cells (S5); Methods > Chemicals and antibodies (S69); Methods > Cell viability assay (S75); Fig. 1 legend (S126)

Cell viability was measured by MTT assay: Cell viability was measured by MTT assay — Results > Cytotoxic effects of vincristine and SAHA, alone and in combination, on human leukemic MOLT-4 cells (S5); Fig. 1 legend (S126)

Vincristine reduces bone marrow colony formation

Cell-based study · bone marrow of wild-type animals [2]

Bone marrow of wild-type animals was incubated continuously with Vincristine at 100 ng ml−1. Colony numbers were reduced by more than 90% relative to control wells without the drug.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
number of coloniescolony number Wild type; 100 ng ml−1; incubated continuously: more than 90% reduction[2]

Literature-Reported Treatment Conditions

Treatment concentration
100 ng ml−1
Exposure duration
Colonies were scored by day 5.
Method
incubated continuously
Reported limits
Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Vincristine

The paper names Vincristine without stating the salt or form; not verified as the sulfate form supplied as A10973. No dose conversion or lot validation.

RESULTS (S39); Table 1 legend (S104, S105, S106); Table 1 (T1.h1, T1.r1)

number of colonies: number of colonies; comparator: control wells without the drug — Table 1 legend (S104, S106); Table 1 (T1.h1, T1.r1)

Mitochondrial membrane potential following Vincristine treatment

Cell-based study · MOLT-4 cells [1]

MOLT-4 cells were treated with Vincristine alone at 3 nM. Treatment was insufficient to affect mitochondrial membrane potential at 12, 24, 36, and 48 h.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
mitochondrial membrane potentialReported result vincristine alone (3 nM), at different time intervals (12, 24, 36, and 48 h): insufficient to affect the mitochondrial membrane potential[1]

Literature-Reported Treatment Conditions

Treatment concentration
3 nM
Exposure duration
12, 24, 36, and 48 h
Vehicle
DMSO (dimethylsulfoxide)
Reported limits
Not stated in the sentences used: route, control.
Methods and source locations

Compound reported in the paper: Vincristine

The paper names Vincristine without stating the salt or form; not verified as the sulfate form supplied as A10973. No dose conversion or lot validation.

Results > Effects of SAHA in combination with vincristine on the apoptotic pathway and HDAC activity in human leukemic MOLT-4 cells (S37); Methods > Chemicals and antibodies (S69); Fig. 4 legend (S145, S146)

mitochondrial membrane potential: mitochondrial membrane potential — Results > Effects of SAHA in combination with vincristine on the apoptotic pathway and HDAC activity in human leukemic MOLT-4 cells (S37); Fig. 4 legend (S145, S146)

Vincristine sulfate In Vivo Studies

C57BL/6J mice received Vincristine sulfate at 0.5 mg/kg i.p. At 24 h, infiltration of F4/80+ cells into the sciatic nerve increased compared with PBS control, reaching 141.4 ± 16.4 cells/ mm2. [3]

Vincristine increases sciatic nerve cell infiltration

Animal study · C57BL/6J mice; n = 7 [3]

C57BL/6J mice received Vincristine sulfate at 0.5 mg/kg i.p. At 24 h, sciatic nerve infiltration by F4/80+ cells increased compared with PBS control, reaching 141.4 ± 16.4 cells/ mm2.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
infiltration of F4/80+ cells into the sciatic nerveF4/80+ cells 0.5 mg/kg i.p., 24 h: 141.4 ± 16.4 cells/ mm2[3]

Conditions shared by the study groups

Route
i.p.
Treatment course
24 h
Vehicle
sterile Dulbecco’s PBS
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Vincristine sulfate 0.5 mg/kgPBS controlincreased infiltration of F4/80+ cells into the sciatic nerve (141.4 ± 16.4 cells/ mm2; n = 7; Fig. 2, B and C; P < 0.05 compared with PBS control)[3]
Vincristine sulfate 0.5 mg/kg
Model: C57BL/6J mice; n = 7
Methods and source locations

Compound reported in the paper: Vincristine sulfate; Compound label in the paper: Vincristine

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > Peripheral neuro-inflammation causes vincristine-induced mechanical allodynia (S6, S7); Materials and methods > Drug administration for neuropathy studies (S99); Materials and methods > Immunohistochemistry (IHC) and histomorphometric methods (S148)

infiltration of F4/80+ cells into the sciatic nerve: infiltration of F4/80+ cells into the sciatic nerve; comparator: PBS control — Results > Peripheral neuro-inflammation causes vincristine-induced mechanical allodynia (S7)

Vincristine sulfate 0.5 mg/kg · Results > Peripheral neuro-inflammation causes vincristine-induced mechanical allodynia (S7)

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 2068-78-2
Applications Tubulin inhibitor
Formula C46H56N4O10.H2SO4
Molecular Weight 923
Synonyms Leurocristine; VCR
SMILES
CC[C@@]1(C[C@@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 86 mg/mL (93.16 mM)
Water 52 mg/mL (56.33 mM)
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
28 mg/mL
Vehicle
Saline

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Vincristine sulfate Research References

  1. [1] Chao MW, Lai MJ, Liou JP, et al. The synergic effect of vincristine and vorinostat in leukemia in vitro and in vivo. J Hematol Oncol (2015). PMID: 26156322 DOI: 10.1186/s13045-015-0176-7 Source material
  2. [2] van Tellingen O, Buckle T, Jonker JW, et al. P-glycoprotein and Mrp1 collectively protect the bone marrow from vincristine-induced toxicity in vivo. Br J Cancer (2003). PMID: 14583783 DOI: 10.1038/sj.bjc.6601363 Source material
  3. [3] Starobova H, Monteleone M, Adolphe C, et al. Vincristine-induced peripheral neuropathy is driven by canonical NLRP3 activation and IL-1β release. J Exp Med (2021). PMID: 33656514 DOI: 10.1084/jem.20201452 Source material

Added to your cart

View Cart Checkout
Loading...